Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health, NeoGenomics Partner on Oncology Drug Clinical Trials and Testing

NEW YORK – Genetron Health announced on Monday that it has entered into a strategic partnership with NeoGenomics to assist with drug developers' clinical trials.

The firms will use their technology platforms and product pipelines to help business partners synchronize global clinical drug trials and companion diagnostics development, Genetron said in a statement. The collaboration will include developing and operating clinical trials for both oncology drugs and their corresponding CDx products, Genetron added.

Genetron will be able to assist providers and researchers who need a China arm for global or China-focused clinical trials, while NeoGenomics will support Genetron with trials outside of China based in the US, Asia-Pacific, Europe, or the Middle East.

Combined, the companies' resources include 15 CLIA-certified and College of American Pathologists-accredited laboratories and a clinical drug trial and pharmaceutical services team.

"The combination of NeoGenomics' global pharma services and clinical trials expertise and Genetron Health's experience adopting international healthcare products for the China market will enhance our overall drug R&D support capacity," Gina Wallar, president of pharma services at NeoGenomics, said in a statement. "This will enable NeoGenomics to better serve the needs of global drug R&D clinical trial projects."